This FTSE 100 stock would’ve tripled my money in 10 years. Can it happen again?

Manika Premsingh holds this FTSE 100 stock in her portfolio already, but is now wondering if it is likely to continue rising like it has in the past. 

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Plenty of high performing stocks are part of the FTSE 100 index. But not every stock is made equal. Some are definitely better buys than others and have managed to reward investors again and again. Like the the healthcare star AstraZeneca (LSE: AZN). If I had bought it 10 years ago, it would have tripled my money by now. 

AstraZeneca’s eye-watering valuation

I know that on the face of it, it comes with risks. A big one is its market valuation. I spend a fair bit of time researching cheap stocks, because they might just have the potential to rise significantly more than pricey ones. And by that argument, AstraZeneca should be an absolute no-go. Right now, it has an unbelievable price-to-earnings (P/E) ratio of 1,510 times as per my calculations based on its recently released full-year earnings report. The only other stock I have seen with such high valuations is Tesla, and there is no way I am about to buy it. 

Scratching the surface

If I dig deeper into this story, however, it turns out that AstraZeneca’s full-year 2021 P/E has risen to crazy levels only because of a massive fall in its reported earnings, which needs to be taken with a healthy measure of salt in my view. That is because the latest drop is driven partly by the company’s acquisition of US-based rare diseases’ focused company Alexion, a move whose potential impact I had wondered about earlier as well. It is also down because of items like restructuring, amortisation, and impairments. 

If I instead consider the core earnings measure, the number that removes the noise and focuses on the earnings from the main business, it is much healthier. And it gives me a P/E of 22 times, which I think is a truer reflection of the company’s valuation. The reported number is too much of an outlier in my view to give any real perspective!

What is really going on with this FTSE 100 stock?

At this valuation, AstraZeneca does not look terrible expensive to me. I mean it is not significantly higher than that for the FTSE 100 at 16 times. And this is a healthy defensive, with a good outlook for the current year. Speaking of its outlook, the company is optimistic despite the fact that its Covid-19 related numbers are expected to weaken as the pandemic’s grip wanes. Its crucial cancer treatments are likely to hold it in good stead over the foreseeable future. And it helps that it is adding to its portfolio of products, like through the acquisition of Alexion. 

I first bought the stock a few years ago, and occasionally buy it on dips even now. It has not disappointed me so far, I look forward to buying more of it in the near future. And holding it for a long time. Because I think it could triple my money over the next decade as well. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh owns AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bronze bull and bear figurines
Investing Articles

US stock market: the winners and losers one week after the election

Last week's US election spurred big moves in the US stock market, with some global indexes making record highs. Here's…

Read more »

Investing Articles

The latest FTSE dip has handed me a brilliant opportunity to buy cheap shares!

Harvey Jones is on a mission to take advantage of the recent FTSE 100 dip by going shopping for cheap…

Read more »

Investing Articles

After falling 13% this ultra-high-income share yields 7.25% with a P/E of just 10.1!

Harvey Jones couldn't resist buying this FTSE income share. He thought it looked great value in September and it's even…

Read more »

The flag of the United States of America flying in front of the Capitol building
Growth Shares

2 FTSE 100 stocks that could soar while Donald Trump is US President

These two FTSE 100 companies have a lot of exposure to North America. So, they stand to benefit from a…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,000 of savings? Here’s how I’d aim to turn that into £5,832 a year of passive income!

Smaller initial investments in high-yielding stocks can generate much greater passive income over time, especially if dividend compounding is used.

Read more »

Investing Articles

Will the Lloyds share price drop to 50p in 2025 and should I buy the stock if it does?

The Lloyds share price has fallen 12% in six weeks, making the stock cheaper on a price-to-book basis than NatWest.…

Read more »

Investing Articles

As BT’s share price drops 8%, should I buy more?

BT’s share price looks a bargain to me on several key stock measurements, offering a high yield as well, supported…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

After falling 87% in 45 months, could Dr Martens be a winning value stock?

Ahead of its half-year results due to be released later this month, our writer considers whether this FTSE 250 icon…

Read more »